Tomer Hertz
Overview
Explore the profile of Tomer Hertz including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
41
Citations
1935
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
21.
Fiore-Gartland A, Manso B, Friedrich D, Gabriel E, Finak G, Moodie Z, et al.
PLoS One
. 2016 Feb;
11(2):e0147812.
PMID: 26863315
The interferon gamma, enzyme-linked immunospot (IFN-γ ELISpot) assay is widely used to identify viral antigen-specific T cells is frequently employed to quantify T cell responses in HIV vaccine studies. It...
22.
Walsh S, Moodie Z, Fiore-Gartland A, Morgan C, Wilck M, Hammer S, et al.
J Infect Dis
. 2015 Oct;
213(4):541-50.
PMID: 26475930
Background: Increasing the breadth of human immunodeficiency virus type 1 (HIV-1) vaccine-elicited immune responses or targeting conserved regions may improve coverage of circulating strains. HIV Vaccine Trials Network 083 tested...
23.
Yoon S, Chen N, Ducatez M, McBride R, Barman S, Fabrizio T, et al.
Sci Rep
. 2015 Aug;
5:12828.
PMID: 26269288
The virologic factors that limit the transmission of swine influenza viruses between humans are unresolved. While it has been shown that acquisition of the neuraminidase (NA) and matrix (M) gene...
24.
Edlefsen P, Rolland M, Hertz T, Tovanabutra S, Gartland A, deCamp A, et al.
PLoS Comput Biol
. 2015 Feb;
11(2):e1003973.
PMID: 25646817
The RV144 clinical trial showed the partial efficacy of a vaccine regimen with an estimated vaccine efficacy (VE) of 31% for protecting low-risk Thai volunteers against acquisition of HIV-1. The...
25.
Gartland A, Li S, McNevin J, Tomaras G, Gottardo R, Janes H, et al.
J Virol
. 2014 May;
88(15):8242-55.
PMID: 24829343
Unlabelled: The RV144 HIV-1 vaccine trial demonstrated partial efficacy of 31% against HIV-1 infection. Studies into possible correlates of protection found that antibodies specific to the V1 and V2 (V1/V2)...
26.
Oshansky C, Gartland A, Wong S, Jeevan T, Wang D, Roddam P, et al.
Am J Respir Crit Care Med
. 2013 Dec;
189(4):449-62.
PMID: 24308446
Rationale: Children are an at-risk population for developing complications following influenza infection, but immunologic correlates of disease severity are not understood. We hypothesized that innate cellular immune responses at the...
27.
Keating R, Hertz T, Wehenkel M, Harris T, Edwards B, McClaren J, et al.
Nat Immunol
. 2013 Oct;
14(12):1266-76.
PMID: 24141387
Highly pathogenic avian influenza viruses pose a continuing global threat. Current vaccines will not protect against newly evolved pandemic viruses. The creation of 'universal' vaccines has been unsuccessful because the...
28.
Hertz T, Oshansky C, Roddam P, DeVincenzo J, Caniza M, Jojic N, et al.
Proc Natl Acad Sci U S A
. 2013 Jul;
110(33):13492-7.
PMID: 23878211
Experimental and computational evidence suggests that HLAs preferentially bind conserved regions of viral proteins, a concept we term "targeting efficiency," and that this preference may provide improved clearance of infection...
29.
Hertz T, Ahmed H, Friedrich D, Casimiro D, Self S, Corey L, et al.
PLoS Pathog
. 2013 Jul;
9(6):e1003404.
PMID: 23818843
Several recent large clinical trials evaluated HIV vaccine candidates that were based on recombinant adenovirus serotype 5 (rAd-5) vectors expressing HIV-derived antigens. These vaccines primarily elicited T-cell responses, which are...
30.
Kunwar P, Hawkins N, Dinges W, Liu Y, Gabriel E, Swan D, et al.
PLoS One
. 2013 Jun;
8(5):e64405.
PMID: 23741326
A successful HIV vaccine will likely induce both humoral and cell-mediated immunity, however, the enormous diversity of HIV has hampered the development of a vaccine that effectively elicits both arms...